Objectives To compare quantitative magnetic resonance imaging (MRI) and power Doppler ultrasonography (PDUS) with conventional measures of disease activity in rheumatoid arthritis (RA) patients treated with the antiinterleukin 6 (anti-IL 6) receptor antibody tocilizumab in terms of responsiveness at a few months to disease activity and ability to predict structural damage at 1 year.
Introduction
Tocilizumab is a humanized anti-interleukin 6 (anti-IL 6) receptor antibody [1] that has been demonstrated in previous clinical trials to improve the signs and symptoms of RA and prevent radiographic progression [2] [3] [4] [5] [6] [7] [8] . Structural damage in RA has traditionally been assessed by conventional radiography and disease activity by individual core set variables as well as different composite indices such as the disease activity score (DAS), simplified disease activity index (SDAI), and clinical disease activity index (CDAI) [9] [10] [11] [12] . In recent years, magnetic resonance (MR) imaging and ultrasonography (US) have increasingly been used as outcome measures in clinical trials of RA [13] [14] [15] [16] . Quantitative analysis in magnetic resonance imaging and US theoretically have advantages over semiquantitative analysis in measuring the response to therapeutic agents, as the former can reflect a change in inflammatory activity more sensitively and objectively.
The Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) has developed procedures to reach a consensus on which measures to apply in clinical trials [17] . The main objective in clinical trials is the measurement of change (e.g., monitoring treatment effect) and, in this setting, the concept of responsiveness may be the most important characteristic of an outcome measure when deciding which particular instrument to use in a clinical trial [18, 19] . A more responsive measure has obvious advantages including reduction of sample sizes for clinical studies. The most accepted means to measure therapeutic effect is OMERACT-RAMRIS (RA MRI scoring system). The RAMRIS consists of semiquantitative assessment of bone erosion, bone marrow edema, and synovitis and is sensitive to change over weeks as well as months [20] [21] [22] . RAMRIS is being used increasingly in trials of biological agents to measure changes in these markers for disease activity. Recent work has shown that in a cohort of patients receiving tumor necrosis factor alpha (TNFα) treatment, the MR total inflammation score displayed responsiveness superior to conventional measures of disease activity, indicating its promise as an outcome measure in clinical studies and for clinical practice [23] . However, less is known about the responsiveness of imaging measures during intervention with anti-IL6 treatment.
The main objective of this study was to assess inflammatory changes in RA patients during the first few months of anti-IL6 treatment by MR imaging and power Doppler ultrasonography (PDUS) measures, using conventional semiquantitative and newly introduced quantitative assessment. We compared these measures with conventional measures of disease activity in terms of their responsiveness to disease activity and ability to predict structural damage at 1 year.
Materials and methods

Patients
This prospective study was approved by the institutional review board; patients and control subjects gave written informed consent. In the prospective study to investigate the value of analysis of image and clinical parameters in rheumatoid patients treated with tocilizumab, 29 consecutive patients were available for testing at baseline and for 2-and 5-month follow-ups with PDUS and MR studies including non-contrast and contrast imaging sequences. Radiographs of the hands were evaluated at baseline and follow-up at 12 months when available. All patients satisfied the American College of Rheumatology revised 1987 criteria for RA [24] . A portion of our patient population has been previously reported [25] .
Tocilizumab therapy
Each patient received intravenous injections of monotherapy (8 mg/kg intravenously every 4 weeks). The dose, type, and combination of disease-modifying antirheumatic drugs (DMARDs) and/or immunosuppressants could differ according to disease activity at the discretion of the treating physician. The doses of other drugs that each patient was taking were not changed during the study period. Patients had received stable doses of DMARDs for ≥8 weeks prior to study entry. Oral glucocorticoids (≤10 mg/day prednisone or equivalent) and nonsteroidal anti-inflammatory drugs (NSAIDs) were permitted if the doses were stable for ≥4 weeks.
Clinical assessment
Clinical evaluation was performed for each patient by one of the five rheumatologists (K.T, S.M, M.M, F.J, and K.Y), all of whom were blinded to the imaging findings.
Laboratory assessment
Serum markers of inflammation, C-reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR) were obtained on the same day as MR imaging.
Disease activity assessment
In the assessment of disease activity, DAS28-ESR (erythrocyte sedimentation rate) was used. The DAS28-ESR is determined as DAS28-ESR = 0.555 × (TJC) 0.5 +0.284× (SJC) 0.5 +0.7×ln(ESR)+0.0142×(VAS), indicating how active the rheumatoid arthritis is at the moment [26] , where TJC is the tender joint count, SJC is the swollen joint count, and VAS is the visual analog scale.
PDUS assessment
PDUS was performed at baseline, and at 2 and 5 months by one of the three ultrasonographers (H.M, S.F, N.A) specializing in musculoskeletal US, who have 2, 7, and 8 years of experience, respectively. They were blinded to other clinical information. A 13-MHz linear array transducer was used (Hitachi EUP-L34P, Hitachi, Tokyo, Japan). Pulse Doppler settings were standardized for the detection of synovial blood flow by adjusting color gain, pulse repetition, and flow optimization parameters according to the method in a previous study [27] . Power Doppler settings (75 dB dynamic range, medium persistence, medium frame rate, low wall filter, 1,300 Hz pulse repetition frequency, medium vein flow optimization, 1,300 Hz speed velocity) were identical throughout the examinations. Room temperature was kept at 25°C. The patients were positioned comfortably, and examinations were started after 10 min stabilization of pulse rate. The scanning technique on each finger was standardized and fixed: for the first through fifth metacarpophalangeal (MCP) joints, scanning was performed in the longitudinal plane over the dorsal surface of the joint with light skin pressure. The basic scanning technique followed the EULAR guidelines [28] . The synovial vascular area with the most pronounced power Doppler activity was identified from the cine-loop and stored. The PDUS images were recorded on the hard drive of the ultrasonographic machine. All examinations were completed within 15 min. Semiquantitative grading has been described in previous studies (0=absence of signal, 1=single vessel dots, 2=vessel dots over less than half of the synovial area, 3=vessel dots over more than half of the synovial area) [29] . This grade for each joint was defined as the joint grade for the power Doppler signal (JGPD). Representative images for each JGPD are shown in Fig. 1 . The sum of JGPD for 10 MCP (bilateral 1-5 MCP) joints was defined as JGPD-10. Quantitative PDUS is the number of vascular flow pixels in the region of interest (ROI). The ROI was a standardized box type (5×10 mm), which was located to contain as many of the vascular flow pixels as possible. Vascular flow pixels in the ROI were measured automatically using the vascularity mode of the ultrasonographic machine (Hitachi EUB-6500, Hitachi, Tokyo, Japan). The joint index for the power Doppler signal (JIPD) represented the vascular flow pixels in the ROI for each joint ( image to show the region of interest (ROI) setting for volumetry. The volume of the MR signal was measured for wrists and MCP joints (distal ulna, distal radius, carpal bones, metacarpal bones, 1-5 metacarpophalangeal joints, and soft tissue), 1 cm proximal to the wrist joints and 1 cm distal to the MCP joints. By observing 2D and 3D images side by side, multiple slices were assessed on 2D images while contouring the ROI on 3D images to ascertain that the ROI was set appropriately. d Volumetry applying threshold. One point five (1.5) times the muscle signal [for this representative case, 94.2 (= 62.8× 1.5)] was applied to the region of interest (ROI), resulting in volumes of 11.8 cc. The threshold for the 3D STIR image was determined according to the previous study to define the optimal threshold based on the muscle signal [25] OMERACT-RAMRIS (confined to the wrist) was carried out on both wrists of all subjects by an experienced radiologist (K.T.) who was blinded to other clinical information [22] . The scoring was repeated twice with a 2-month interval, and intraobserver variability was assessed.
We introduced a simple volumetry method using STIR image data for the pannus by setting the muscle signal as a threshold in the pilot study [25] . Briefly, the pannus was visualized as a high signal on STIR images; in contrast, normal muscle was low signal intensity on STIR. We set a region of interest (ROI) of 10 mm 2 in the left adductor pollicis muscle on a STIR coronal image and measured the average signal in the ROI for a standard for the threshold (Fig. 3a) . The volume of the signal was measured to cover the wrists and MCP joints (distal ulna, distal radius, carpal bones, metacarpal bones, 1-5 metacarpophalangeal joints, and soft tissue), 1 cm proximal to the wrist joints and 1 cm distal to the MCP joints (Fig. 3b, c) . The coverage of the volumetry was expanded for this study to include the MCP joints in addition to the wrists. We set 1.5 times the muscle signal as the threshold, and the volume of abnormal signals was obtained using three-dimensional coronal maximum intensity projection (3D coronal MIP) STIR image (Fig. 3d) ; we defined this volume as V_MRI. This volumetry was carried out by two MR technologists independently.
Radiography and assessment
Radiographs of hands were obtained at baseline and at the 1-year follow-up. Radiological assessments were examined for bilateral hands twice with a 2-month interval according to the Genant-modified Sharp score by a radiologist (K.T.) who was blinded to other clinical information [30] .
Statistical analysis
Statistical analyses were calculated with the use of the Excel program (Microsoft, Redmond, WA, USA) and MedCalc program 10.4.5.0 (MedCalc Software, Mariakerke, Belgium). Intra-and interobserver reliabilities were estimated using calculations of intraclass correlation coefficients (ICC). The ICC ranged from −1 to +1. ICC values are interpreted as follows: <0.40, poor to fair agreement; 0.41 to 0.60, moderate agreement; 0.61 to 0.80, substantial agreement; 0.81 to 1.00, almost perfect agreement [20] . Quantitative variables (clinical, laboratory, PDUS, MR imaging, and RAMRIS) were given as median, interquartile range, and range. All statistical analyses were undertaken using the MedCalc program 10.4.5.0 (MedCalc Software, Mariakerke, Belgium). The standardized response mean (SRM) was calculated as the ratio of the mean change in the measure and the standard deviation of the mean change scores. The term "responsiveness" denotes the magnitude of change or sensitivity to change over time. To quantify responsiveness, several effect sizes have been proposed as estimates of the amount of change detected with an instrument, resulting in a wide variety of effect size indices [31] [32] [33] . It is not yet known which of these statistics is the better for assessing responsiveness, although there is some evidence to suggest that it is better to estimate the magnitude of the change using the SD of the change score (i.e., SRM) in the denominator compared with the SD at baseline (i.e., effect size) [34] [35] [36] . We therefore chose to assess responsiveness using SRM. There is no universal agreement on how to interpret the magnitude of the SRMs, but in most cases the thresholds introduced by Cohen for effect sizes (ES) were applied: "trivial" (ES<0.20), "small" (0.20≤ES<0.50), "moderate" (0.50≤ES<0.80) , or "large" (0.80≤ES) [31] . Correlations between clinical, laboratory, PDUS, MR imaging, and radiographic parameters were analyzed by Pearson's or Spearman's rank correlation test according to the variable distribution. The course of the process variables was obtained by calculating time-integrated values (TIV) using the areaunder-the-curve method [37] . Any P value less than 0.05 was considered statistically significant.
Results
Measured quantities, abbreviations, and possible ranges are shown in Table 1 . The demographic characteristics and immunological/therapeutic status are listed in Table 2 . The clinical measures of disease activity and imaging measures at baseline, and 2 and 5 months are summarized in Tables 3  and 4 , respectively. Both intraobserver reliability for RAMRIS and Genantmodified Sharp score by a radiologist were in almost perfect agreement (ICC=0.840 and 0.9137, respectively). Interobserver reliability for V_MRI between two technologists showed substantial agreement (ICC = 0.7449).
Representative MR and PDUS images to show the therapeutic effect are shown in Figs. 4 Table 4 The imaging measures at baseline, and 2 and 5 months
The mean changes and SRMs of the measures from baseline at 2 and 5 months are presented in Table 5 . At the 2-month follow-up there was a marked (moderate to large) treatment response in clinical measures, and the same tendency was observed at 5 months. The SRMs for imaging measures were trivial to small at 2 and 5 months, except for MR erosion, which showed a moderate response. The SRM for QMRI and QPDUS had negative values, and they were more sensitive than semiquantitative imaging measures (small versus trivial) at 2 months. RAMRIS synovitis, SQPDUS, and PDUS had small responses with negative values at 5 months. Table 6 shows the correlation between the measures and structural damage/damage progression assessed with radiography and MRI. Structural damage progression for radiography was correlated with TIV of MR bone erosion (r=0.6476, P=0.0167). Structural damage progression for MR erosion was correlated with TIV of JIPD-10 (r=0.5573, P=0.0478). The TIV of DAS28-ESR was not correlated with 1-year structural damage progression for either radiography or MR erosion.
Discussion
This study has shown that conventional measures of disease activity provide superior responsiveness to imaging measures of inflammation in patients with RA treated with anti-IL 6 medication. However, conventional measures of disease activity had poor correlation with 1-year structural destruction progression. Traditional treatment goals for patients with RA include reduction of inflammation (i.e., relieving signs and symptoms), improving physical functioning, and inhibiting the progression of joint damage. Evaluation of disease activity in RA is not easy, and no single marker can reflect all these aspects. A reliable measure should show good responsiveness and allow prediction of future structural damage. While prescribing the anti-TNFα medication for chronic a b Fig. 4 A 72-year-old man with rheumatoid arthritis. Power Doppler images of the second metacarpophalangeal joint of the right finger at baseline (a) and 5 month follow-up (b) study are shown. Both of these images correspond to grade 3 in the conventional power Doppler grading (vessel dots over more than half the synovial area). When a rectangular region of interest (ROI) of 10×5 mm was selected (white box), the number of pixels with a positive Doppler signal was 40 at the baseline (a) and 29 at the 5-month follow-up (b). This is an example to show that quantitative power Doppler analysis is more sensitive to therapeutic change than semiquantitative analysis RA patients, Haavardsholm et al. reported that the MR total inflammation score displayed superior responsiveness to conventional measures of disease activity and may be a promising outcome measure in clinical studies and for clinical practice [23] . However, we have observed that this finding is not applicable to patients with RA treated with anti-IL 6 medication. This is explained by the fact that anti-IL 6 medication directly inhibits the production of acute phase proteins, such as CRP and fibrinogen from hepatocytes, by directly inhibiting the action of IL-6. Consequently, the CRP level and ESR rapidly and intensively decrease with the initiation of anti-IL 6 treatment before any improvement in swollen or tender joint counts is observed [6] , possibly resulting in a discrepancy between an improvement in inflammatory markers and an improvement in actual RA disease activity [38] . In semiquantitative MR measures, MR bone erosion may be useful, with moderate responsiveness at month 5 and with correlation between radiography changes. Other MR measures are not useful: MR synovitis showed no and small responsiveness at months 2 and 5, respectively, and there was no statistically significant correlation between future radiography or MR bone lesion progression. Although previous studies have suggested MR bone edema most closely predicts bone damage [39] [40] [41] , MR bone erosion had better correlation with radiography changes than bone marrow edema in this study. This may be explained by a limited number of patients included and by difficulty in our MR protocols to clearly distinguish bone edema from bone erosion due to a decreased spatial resolution. Quantitative MR imaging showed small and trivial responsiveness at months 2 and 5, respectively, and there was no statistically significant correlation with future radiography or MR bone lesion progression. Quantitative MR imaging was shown to reflect the improvement of MR synovitis and erosion according to the previous study [25] .
In PDUS measures, quantitative PDUS was more responsive than semiquantitative PDUS (small versus trivial) at month 2, and both were small at month 5. The correlation of the cumulative PDUS measure with MR bone lesions was statistically significant. This may show that quantitative PDUS is more useful than semiquantitative PDUS measures. A comparison of the two methods revealed that the quantitative PDUS method strongly correlates with the semiquantitative PDUS in terms of RA assessment [27, 42] ; moreover, the change of synovial vascularity in a single finger joint determined by the quantitative PDUS could numerically predict its radiographic progression in RA patients treated with methotrexate [43] . This study may constitute further evidence to support the suggestion that quantitative PDUS is more sensitive to changes in synovial activity and thus predictive of future structural damage.
The present study included a rather small number of patients and had no control/placebo group; the number of participants was even smaller for the 1-year follow-up See Table 1 for abbreviations data (13 out of 29 patients), with no difference in DAS28-ESR, JGPD-10, JIPD-10, MR synovitis, MR bone edema, or MR bone erosion between follow-up (+) and follow-up (−) groups (P values were 0.37, 0.49, 0.52, 0.41, 0.41, and 0.61, respectively, for independent t-test). However, all patients had active disease, and the intervention with a potent drug, combined with a very extensive data collection of outcome measures, allowed comparisons of the responsiveness of these measures in a real-life setting. Another limitation may be that a relatively larger field of view was selected for MR data acquisition, possibly resulting in decreased spatial resolution compared with parameter setting for a dedicated joint study. Thus, this study may have underestimated the value of MR imaging in terms of responsiveness and prediction of future progression in structural damage during treatment. In this cohort of patients receiving the anti-IL 6 receptor antibody tocilizumab, we have shown that conventional measures are responsive but less reflective of future bone destruction than image analysis. In the evaluation of disease activity in RA patients within 1 year of beginning treatment with the anti-IL 6 receptor antibody tocilizumab, MR bone erosion and quantitative PDUS may be both responsive and predictive of structural damage progression at 1 year. Δ indicates difference in value between baseline and 1-year follow-up. See Table 1 for abbreviations
